The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers1
Abstract
Osteoporosis in men poses a unique therapeutic challenge. Clinical studies have focused largely on the more prevalent problem of post-menopausal osteoporosis, with few gender-specific studies exploring treatment options in men. Idiopathic osteoporosis in middle-aged men presents an additional dilemma, because in the majority of patients it is a low bone turnover state for which there are currently no available anabolic agents. We conducted an 18-month randomized, double blind, placebo-controlled trial of 23 men with idiopathic osteoporosis, 30-68 yr old (mean age +/- SEM, 50 +/- 1.9 yr). All patients received 1,500 mg calcium and 400 IU vitamin D daily. Ten patients were randomized to receive 400 IU PTH-(1-34), and 13 patients received vehicle, administered by daily sc injection. Serum and urinary biochemistries, including markers of bone turnover were measured every 3 months. Bone densitometry of the lumbar spine, hip, and radius was performed every 6 months. PTH-(1-34) was associated with a marked 13.5% increase in bone mass at the lumbar spine, whereas that in the control group did not change (P < 0.001). The mean lumbar spine T-score improved from -3.5 +/- 0.2 to 2.4 +/- 0.4. Femoral neck bone mineral density in the PTH-treated group increased 2.9% (P < 0.05). The 1/3 site of the distal radius showed no change from baseline in the PTH-treated group. There were no significant changes in serum calcium concentration, 24-h urinary calcium excretion, or 1,25-dihydroxyvitamin D in either group. All markers of bone turnover increased in the PTH-treated patients, with the greatest changes in serum osteocalcin and urinary N-telopeptide (230% and 375% above baseline by 12 months, respectively; P < 0.001). Free pyridinoline and markers of bone formation that showed little correlation with each other at baseline, became highly correlated in the PTH-treated group (r = 0.1; P = 0.29 at baseline; to r = 0.7; P < 0.0001 at 18 months), a pattern absent in the control patients. The best predictor of the lumbar spine response to PTH at 18 months was the combination of pyridinoline at baseline and osteocalcin at 3 months (70% of the variance). PTH is a potent stimulator of skeletal dynamics in men with idiopathic, low turnover osteoporosis; is associated with substantial increases in lumbar spine and hip bone density; and may prove to be an efficacious anabolic agent in men with this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Nussbaum, S. R., Zahradnik, R. J., Lavigne, J. R., Brennan, G. L., Nozawa-Ung, K., Kim, L. Y., Keutmann, H. T., Wang, C. A., Potts, J. T., & Segre, G. V. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.8.1364 · Cited by 808
Long-Term Estrogen Replacement Therapy Prevents Bone Loss and Fractures
ETTINGER, B., GENANT, H. K., & CANN, C. E. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-3-319 · Cited by 774
The Prevention and Treatment of Osteoporosis
Wood, A. J. J., Riggs, B. L., & Melton, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270908 · Cited by 754
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Self-citationAnabolic Actions of Parathyroid Hormone on Bone*
DEMPSTER, D. W., COSMAN, F., PARISIEN, M., SHEN, V., & LINDSAY, R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-690 · Cited by 717
Self-citationHanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Reeve, J., Meunier, P. J., Parsons, J. A., Bernat, M., Bijvoet, O. L., Courpron, P., Edouard, C., Klenerman, L., Neer, R. M., Renier, J. C., et al. (1980) · BMJ · doi:10.1136/bmj.280.6228.1340 · Cited by 582
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559
Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Pierini, E., & Arnaud, C. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3914 · Cited by 529
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Dr. Slovik, D. M., Rosenthal, D. I., Doppelt, S. H., Potts, J. T., Daly, M. A., Campbell, J. A., & Neer, R. M. (1986) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650010411 · Cited by 348
Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: A Retrospective Analysis
Hajjar, R. R., Kaiser, F. E., & Morley, J. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3793 · Cited by 325
Proximal femur bone mineral levels of US adults
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., Johnston, C. C., & Lindsay, R. L. (1995) · Osteoporosis International · doi:10.1007/bf01622262 · Cited by 323
Self-citationHollis, B. W. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.11.2060 · Cited by 295
Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency
Finkelstein, J. S., Klibanski, A., Schaefer, E. H., Hornstein, M. D., Schiff, I., & Neer, R. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412153312404 · Cited by 245
Immunoassay for urinary pyridinoline: The new marker of bone resorption
Seyedin, S. M., Kung, V. T., Daniloff, Y. N., Hesley, R. P., Gomez, B., Nielsen, L. A., Rosen, H. N., & Zuk, R. F. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080515 · Cited by 242
Pak, C. Y. C., Sakhaee, K., Adams-Huet, B., Piziak, V., Peterson, R. D., & Poindexter, J. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-6-199509150-00001 · Cited by 241
Greenspan, S. L., Parker, R. A., Ferguson, L., Rosen, H. N., Maitland-Ramsey, L., & Karpf, D. B. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.9.1431 · Cited by 238
Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial
Lufkin, E. G., Whitaker, M. D., Nickelsen, T., Argueta, R., Caplan, R. H., Knickerbocker, R. K., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1747 · Cited by 237
Epidemiology and clinical features of osteoporosis in young individuals
Khosla, S., Lufkin, E. G., Hodgson, S. F., Fitzpatrick, L. A., & Melton, L. J. (1994) · Bone · doi:10.1016/8756-3282(94)90280-1 · Cited by 199
Hodsman, A. B., Fraher, L. J., Watson, P. H., Ostbye, T., Stitt, L. W., Adachi, J. D., Taves, D. H., & Drost, D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3762 · Cited by 194
Osteoporosis in Men: Diagnosis, Pathophysiology, and Prevention
JACKSON, J. A., & KLEEREKOPER, M. (1990) · Medicine · doi:10.1097/00005792-199005000-00002 · Cited by 186
Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches
Black, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Christensen, L., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.90 · Cited by 186
Insulin-Like Growth Factor-I in Men with Idiopathic Osteoporosis1
Kurland, E. S., Rosen, C. J., Cosman, F., McMahon, D., Chan, F., Shane, E., Lindsay, R., Dempster, D., & Bilezikian, J. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4253 · Cited by 179
Self-citationDr. Anderson, F. H., Francis, R. M., Peaston, R. T., & Wastell, H. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.3.472 · Cited by 178
Delmas, P. D., Vergnaud, P., Arlot, M. E., Pastoureau, P., Meunier, P. J., & Nilssen, M. H. L. (1995) · Bone · doi:10.1016/8756-3282(95)00113-r · Cited by 171
LJUNGHALL, S., JOHANSSON, A. G., BURMAN, P., KÄMPE, O., LINDH, E., & KARLSSON, F. A. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00550.x · Cited by 171
NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS
OVERGAARD, K., RIIS, B. J., CHRISTIANSEN, C., PØADENPHANT, J., & JOHANSEN, J. S. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00443.x · Cited by 169
Finkelstein, J. S., Klibanski, A., Arnold, A. L., Toth, T. L., Hornstein, M. D., & Neer, R. M. (1998) · JAMA · doi:10.1001/jama.280.12.1067 · Cited by 166
Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., & Steer, B. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116273 · Cited by 163
REEVE, J., Davies, U. M., Hesp, R., McNally, E., & Katz, D. (1990) · BMJ · doi:10.1136/bmj.301.6747.314 · Cited by 116
Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis
Reed, B., Zerwekh, J. E., Sakhaee, K., Breslau, N. A., Gottschalk, F., & Pak, C. Y. C. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100812 · Cited by 102
Two direct (nonchromatographic) assays for 25-hydroxyvitamin D.
Bouillon, R., Herck, E. V., Jans, I., et al. (1984) · Clinical Chemistry · doi:10.1093/clinchem/30.11.1731 · Cited by 97
PTH: A future role in the management of osteoporosis?
REEVE, J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110404 · Cited by 97
A Bioassay for Parathyroid Hormone using Chicks
PARSONS, J. A., Reit, B., & Robinson, C. J. (1973) · Endocrinology · doi:10.1210/endo-92-2-454 · Cited by 94
Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis
Johansson, A. G., Lindh, E., Blum, W. F., Kollerup, G., Sørensen, O. H., & Ljunghall, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550792 · Cited by 91
Dempster, D. W. (1993) · Endocrine Reviews · doi:10.1210/er.14.6.690 · Cited by 90
Johansson, A. G., Eriksen, E. F., Lindh, E., Langdahl, B. L., Blum, W. F., Lindahl, A. H., Ljunggren, Ö., & Ljunghall, S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4148 · Cited by 82
Kurland, E. S., Chan, F. K. W., Rosen, C. J., & Bilezikian, J. P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4971 · Cited by 70
Self-citationGundberg, C. M., Wilson, P. S., Gallop, P. M., et al. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.10.1720 · Cited by 59
Clodronate Is Effective in Preventing Corticosteroid-Induced Bone Loss Among Asthmatic Patients
Herrala, J., Puolijoki, H., Liippo, K. K., Raitio, M., Impivaara, O., Tala, E., & Nieminen, M. M. (1998) · Bone · doi:10.1016/s8756-3282(98)00051-9 · Cited by 54
Anderson, F. H., Francis, R. M., Bishop, J., & RAWLINGS, D. J. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.359 · Cited by 47
Mitchell, D., & Lyles, K. W. (1990) · Journal of Gerontology · doi:10.1093/geronj/45.5.m153 · Cited by 37
The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis
Burckhardt, P., & Burnand, B. (1993) · Osteoporosis International · doi:10.1007/bf01623173 · Cited by 30
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Self-citationBone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,093
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035725 · Cited by 829
Orwoll, E., Scheele, W., Paul, S., Adami, S., Syversen, U., Diez-Perez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 776
Metadata
- Authors
- Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-09
- Volume
- 85
- Issue
- 9
- Pages
- 3069-3076
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2106756976
- Cited by
- 360
- References
- 50
- FWCI
- 21.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.